Latus Bio, a biotechnology company specialising in new gene therapy candidates for central nervous system (CNS) disorders, has announced its launch alongside an initial $54m Series A financing.
Samsung Life Science Fund, an investment fund created by Samsung affiliates, will invest in Latus Bio, a US gene therapy development company, according to Samsung Bioepis on Friday. It is the sixth investment made by the fund between Samsung Biologics, Samsung C&T and Samsung Bioepis, to explore new business opportunities in the biotechnology sector. The exact amount of investment has not been disclosed. Latus Bi.
/PRNewswire/ Modi Ventures, a newly launched venture partnership investing in fund managers and founders building companies shaping the future of humanity,.